Waverly Advisors LLC Boosts Stake in GSK PLC Sponsored ADR $GSK

Waverly Advisors LLC boosted its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 1,372.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 290,593 shares of the pharmaceutical company’s stock after acquiring an additional 270,863 shares during the quarter. Waverly Advisors LLC’s holdings in GSK were worth $15,233,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC purchased a new stake in GSK during the fourth quarter valued at about $528,000. Dorsey Wright & Associates purchased a new position in GSK in the 1st quarter worth approximately $2,522,000. Kahn Brothers Group Inc. bought a new stake in GSK during the 2nd quarter valued at $8,305,000. Nvest Financial LLC bought a new position in shares of GSK during the second quarter valued at about $2,236,000. Finally, Fisher Asset Management LLC increased its holdings in GSK by 3.0% during the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock valued at $1,627,931,000 after purchasing an additional 968,370 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GSK shares. Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. HSBC raised GSK from a “reduce” rating to a “hold” rating in a research report on Monday, July 6th. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada began coverage on GSK in a research note on Tuesday. They set a “sector perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, GSK has a consensus rating of “Hold” and an average target price of $53.00.

GSK Stock Performance

Shares of NYSE GSK opened at $48.57 on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $98.24 billion, a price-to-earnings ratio of 15.19, a price-to-earnings-growth ratio of 1.95 and a beta of 0.35. GSK PLC Sponsored ADR has a 12-month low of $39.29 and a 12-month high of $61.69. The firm has a 50 day moving average of $51.56 and a 200 day moving average of $52.99.

GSK (NYSE:GSK) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same period last year, the firm earned $0.47 EPS. GSK’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts anticipate that GSK PLC Sponsored ADR will post 4.83 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a dividend yield of 3.7%. The ex-dividend date is Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. GSK’s payout ratio is 55.63%.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.